Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up Study of Avelumab in Participants from Multiple Parent Trials
2018-003711-21Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of avelumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and 2 more, sponsored by Merck KGaA. Primary endpoint: Treatment-related adverse events and safety profile. Started Feb 2019; status: completed.
02
Drugs
avelumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)transitional cell carcinoma (TCC)ovarian cancer
Beyond the preview
Go deeper on 2018-003711-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003711-21.